期刊
CURRENT MEDICINAL CHEMISTRY
卷 18, 期 18, 页码 2674-2685出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986711796011193
关键词
PI3K; mTOR; Akt; cancer; enzyme inhibitors
资金
- Italian Association for Cancer Research (AIRC)
- Fondazione Cariplo - Ricerca Biomedica
- Regione Piemonte - Ricerca Sanitaria Finalizzata
Phosphoinositide 3-kinases (PI3Ks) control key signaling pathways in cancer cells, leading to cell proliferation, survival, motility and angiogenesis. In several human cancers, activation of PI3Ks results from gain-of-function or over-expression of PI3Ks and/or hyperactivity of up-or downstream players in the pathway. As inhibition of PI3Ks and downstream targets such as mammalian target of rapamycin (mTOR) has been shown to reduce tumor growth in vitro and in preclinical models, several small molecule inhibitors of PI3Ks are currently undergoing clinical trial as novel agents in cancer therapy. These drugs include inhibitors targeting all class I PI3Ks (alpha, beta, gamma, delta isoforms), compounds blocking selective PI3K isoforms and dual inhibitors active on both PI3Ks and mTOR. Herein, we summarize the pharmacology and preliminary clinical data of the main PI3K inhibitors undergoing clinical trial. We will also review the preclinical studies documenting the major effects of systemic PI3K inhibition on non-cancer tissues, which have shed light on potential side effects, caveats and limitations for PI3K blockade in patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据